Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Sorafenib in Untreated Advanced NSCLC
NCT00722969Phase 2Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, sorafenib in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Status: unknown.
02
Drugs
erlotinibsorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00722969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722969.